Skip to main content

Published locations for SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. SGLT2 inhibitors: No benefit or harm in hospitalized COVID-19

User login

  • Reset your password
  • /content/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19
  • /clinicianreviews/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid
  • /emed-journal/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19
  • /familypracticenews/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized
  • /internalmedicinenews/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized
  • /clinicalendocrinologynews/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm
  • /jcomjournal/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19
  • /ecardiologynews/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid
  • /cardiology/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19
  • /infectiousdisease/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized
  • /endocrinology/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19
  • /internalmedicine/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid
  • /familymedicine/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid
  • /residents-0/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19
  • /emergencymedicine/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized
  • /icymi-covid/article/265310/heart-failure/sglt2-inhibitors-no-benefit-or-harm-hospitalized-covid-19